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ABSTRACT 
Targeted therapies have opened new perspectives in clinical oncology. However, 
clinicians have observed a lack of response in a relevant percentage of patients and 
frequent relapse in patients who initially respond. Therefore, a compelling challenge 
is to identify mechanisms underlying resistance and strategies to circumvent these 
hurdles.  
A growing body of evidence indicates that MET, the tyrosine kinase receptor for 
hepatocyte growth factor (HGF), is frequently implicated in resistance to targeted 
therapies. In this review we highlight cell autonomous and non-cell autonomous 
mechanisms through which MET drives resistance, and we discuss some unsolved 
issues related to the selection of patients who could benefit from combined therapies.     
 
 
STATEMENT OF SIGNIFICANCE 
Resistance is, at present, the major limitation toof the efficacy of targeted therapies. 
Inappropriate MET activation is very frequently implicated in the onset of primary 
and secondary resistance to these therapies. Deciphering the role of the HGF/MET 
axis in resistance to different drugs could guide the design of new clinical trials based 
on combinatorial therapies and it might help to overcome, or possibly prevent, the 
onset of resistance. 
 
INTRODUCTION 
Targeted therapies by means of compounds that inhibit a specific target molecule give 
a new perspective in the treatment of cancer (1). In contrast to conventional 
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chemotherapy, which acts mainly on dividing cells, targeted drugs specifically act on 
subpopulations of cells directly involved in tumor progression in a more specific way.  
The frequent alteration of receptor tyrosine kinases (RTK) in human malignancies led 
them to be considered targets for anti-neoplastic therapies; this resulted in the 
development of several inhibitors with strong clinical activity. The concept of 
“oncogene addiction”, that is, the dependence of tumor cells on the constitutive 
activation of a single oncogene for their proliferation and survival, has added further 
rationale to the use of targeted therapies (2). In a fraction of patients with cancer, 
targeted therapies have shown excellent results, leading to dramatic tumor regression. 
However, a substantial percentage of patients selected to express the target of the drug 
do not benefit from treatment (primary resistance) and, almost invariably, initially 
responsive patients develop resistance to treatment and undergo tumor relapse 
(secondary resistance). Therefore, an important challenge associated with targeted 
therapies is to predict mechanisms that could cause resistance to treatment and to find 
ways to solve, or even prevent, this problem. 
Recent studies aimed at investigating the molecular mechanisms responsible for 
primary and secondary resistance to targeted therapies mainly relied on in vitro 
experiments performed in tumor cells. These cells are highly heterogeneous and often 
display genomic instability. The therapeutic treatment can thus select preexisting 
clones with alterations in signaling pathways that are able to compensate for the drug-
inhibited kinase. The use of in vitro models allowed the identification of a number of 
molecular mechanisms responsible for acquired resistance to tyrosine kinase 
inhibitors (TKI). Although most of these mechanisms have also been validated in 
patients, cellular models have clear limitations, such as the artificial growing 
conditions and the lack of epithelial-stromal interactions that typically occur in vivo. 
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Indeed, very recent data support the concept that the tumor microenvironment plays 
an important role in sustaining resistance to targeted therapies, for example, by 
producing ligands that - in a paracrine manner - activate signals able to compensate 
for the drug-inhibited pathways in tumor cells. Thus, an emerging concept is that 
resistance of tumor cells to targeted therapies can be due to cell autonomous and/or 
non-cell autonomous mechanisms. Our knowledge of the prevalence of either 
mechanism in different clinical situations is largely incomplete.  
In this review we will discuss the role of the HGF/MET system in mediating 
resistance to anticancer kinase inhibitors, both in cell autonomous and in non-cell 
autonomous manners, and the translational implications of these findings. 
 
The HGF/MET Pathway 
The MET proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth 
factor (HGF) (3, 4).  Ligand binding induces MET activation, which drives a complex 
biological program defined as “invasive growth”, resulting from the promotion of 
several biological activities such as cell proliferation, cell invasion and protection 
from apoptosis (Figure 1). MET-driven invasive growth is a physiological program 
that occurs during embryonic development and in adulthood during tissue 
regeneration. However, it has been shown that the inappropriate activation of this 
program contributes to several aspects of tumor progression. MET-activated signaling 
pathways are shared with many other RTKs and include the mitogen-activated protein 
kinase (MAPK) and PI3 Kinase-AKT pathways, STAT3, RAC1, and the NF-κB 
pathway (Figure 1). Many studies have focused on the specific role played by each of 
these pathways in the different MET-induced biological activities (for a review see 
(5)).  
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MET-mediated signaling results from pathways directly activated by this receptor, but 
it can also be modulated by the cross talk between MET and different membrane 
receptors, acting in complex interacting networks (Figure 2). In vitro data suggest that 
this cross-talk is not essential for cell survival but  enables a better integration of the 
signals present in the extracellular environment. Under physiological conditions, these 
networks are probably redundant. However, it is likely that under pathological 
conditions these interacting receptors cooperate in promoting tumorigenesis and/or 
metastasis and in inducing resistance to targeted drugs.  The first network of 
interaction involves MET and adhesive receptors such as CD44 and the α6β4 integrin. 
CD44, a transmembrane receptor for hyaluronic acid -  a major component of the 
extracellular matrix - has been implicated in tumor progression and metastasis (6). 
The CD44v6 variant, necessary for the activation of some MET intracellular 
transducers, functions as an amplifying platform, linking the MET cytoplasmic tail to 
the actin cytoskeleton and sustaining activation of the MAPK cascade (7, 8). The 
α6β4 integrin, independent of its adhesive role, acts as a supplementary docking 
platform for amplification of PI-3 Kinase, MAPK, and SRC-dependent pathways (9). 
B family plexins, the receptors for semaphorins, can transactivate MET in the absence 
of HGF and promote pro-invasive signals (10). In addition, the interaction between 
MET and FAS, is important in the modulation of apoptosis (11). MET also interacts 
with other tyrosine kinase receptors, such as those belonging to the EGFR family. In 
fact, reciprocal transphosphorylation between these receptors has been shown in 
different systems and their ability to substitute for each other has been shown in tumor 
cells (12-14).  
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MET/HGF and cancer 
In transformed tissues, gain of an invasive growth program is advantageous for cancer 
progression and metastasis. In fact, constitutive MET activation can contribute to 
several aspects of tumor progression since it induces neoplastic cells to disaggregate 
from the tumor mass, erode basement membranes, infiltrate stromal matrices, and 
eventually colonize new tissues to form metastases (for a review see (15)). 
Data produced by many laboratories provide compelling evidence that HGF/MET 
signaling plays an important role in the development and malignant progression of 
tumors, particularly in tumor invasiveness and metastasis. Preclinical studies show 
that cells ectopically overexpressing MET or HGF are tumorigenic and metastatic in 
nude mice, while MET inhibition decreases these properties (15). Moreover, cancer 
cell lines exhibiting MET gene amplification are “addicted” to MET (which means 
that they are dependent on this receptor for their growth and survival) and MET 
inhibition results either in a block in proliferation or cell death (16-18).  
As shown in Figure 3, deregulated MET activation in cancer can be due to different 
molecular alterations. Clinical data show that MET overexpression, in the absence of 
gene amplification, is the most frequent cause of constitutive MET activation in 
human tumors and often correlates with poor prognosis. Overexpression can be 
caused by several factors, such as hypoxia (19), activation of upstream oncogenes (20, 
21), inactivation of tumor suppressor genes (22) or loss of microRNAs (23, 24). MET 
gene amplification, which drives increased expression and constitutive receptor 
activation, has been described in selected histotypes such as gastro-esophageal, 
colorectal, endometrial and lung carcinomas, glioblastomas and medulloblastomas 
(reviewed in (25)). Autocrine MET activation has been described in sarcoma, 
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glioblastoma, breast carcinoma (reviewed in (25)) and, very recently, in a high 
percentage of acute myelogenous leukemia (26). Finally, the unequivocal evidence 
linking MET and human cancer came from the identification of germline activating 
mutations in patients suffering from ehreditary papillary renal carcinomas (27, 28). 
Activating mutations in sporadically occurring tumors are relatively rare and have 
been mainly found in lung and kidney carcinomas and hepatoblastoma (reviewed in 
(25)). These mutations are located in the tyrosine kinase domain, the juxtamembrane 
portion, or in the extracellular Sema (semaphorin) domain. Although overexpression 
can render MET activation independent from HGF stimulation, in most cases the 
ligand is still required for full receptor activation. This is also true for MET receptor 
variants containing activating mutations that need HGF to fully activate their kinase 
activity (29).  
In light of the functional role played by the HGF/MET axis in different human 
tumors, in the last decade several strategies have been designed to inhibit the 
activation of the MET receptor, and multiple agents are currently in clinical trials (for 
a summary, see Figure.4). 
 
Activation of the HGF/MET axis in sustaining resistance to targeted therapies 
Clinical practice, as well as experimental evidence, has clearly shown that biological 
therapies are effective only in a certain percentage of tumors expressing the 
appropriate target. Moreover, even responding tumors develop resistance to treatment 
quite rapidly. These observations prompted researchers to investigate the mechanisms 
responsible for primary and secondary resistance. The first studies were focused on 
the changes occurring in tumor cells, considered more likely to be responsible for the 
phenomenon due to their high genomic instability (Figure 5). However, many data 
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have unveiled a critical role for the tumor microenvironment in generating and 
sustaining resistance. The tumor stroma, in fact, produces growth factors and other 
molecules (such as extracellular matrix components) that can activate signaling 
pathways in tumor cells that are able to overcome the inhibitory effect of the drug 
(Figure 6).       
 
Cell autonomous role of MET in sustaining resistance to RTK inhibitors 
Non-small cell lung cancer (NSCLC) 
The first clinical evidence of a role of MET in sustaining resistance to EGFR 
inhibitors came from two works studying patients affected by non-small cell lung 
cancer and treated with the reversible EGFR inhibitors gefitinib and erlotinib. 
Engelman and colleagues (30) started from the in vitro observation that lung cancer 
cells, originally sensitive to EGFR inhibitors, became resistant to long-term treatment 
with gefitinib as a consequence of MET gene amplification. They also demonstrated 
that sensitivity to EGFR inhibitors could be restored by simultaneous treatment with 
anti-MET and anti-EGFR drugs, thus proving the causative role of MET in sustaining 
acquired resistance. They observed that MET causes resistance to gefitinib by 
transphosphorylating HER-3 and driving HER3-dependent activation of the PI3K 
pathway. When they analyzed 18 NSCLC patients, all displaying acquired resistance 
to either erlotinib or gefitinib, they found that 22% of these patients displayed MET 
amplification. Notably, one patient bearing two independent metastases showed MET 
amplification only in one metastatic lesion, while the other displayed the EGFR 
T790M mutation, known to impair response to these drugs.  
The work published by Bean and colleagues (31) confirmed these results.  Indeed, 
using high-resolution genome-wide profiling of NSCLCs before and after treatment 
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with anti-EGFR drugs, they found MET amplification in 9 out of 43 patients (21%) 
with acquired resistance, compared with 2 out of 62 (3%) untreated patients. 
Interestingly, they observed that 40% of the samples with MET amplification also 
harbored the EGFR T790M mutation. MET amplification was also found in a NSCLC 
cell line, in which the same cells harbored (i) an EGFR mutation associated with drug 
sensitivity, (ii) an EGFR mutation associated with drug resistance and (iii) MET 
amplification, thus showing that all these genetic lesions can occur within the same 
cell population. Finally, this work also showed that treatment with a MET inhibitor 
was able to overcome acquired resistance to EGFR kinase inhibitors, even in cells 
harboring the T790M mutation.  It has to be noted that more recent studies in re-
biopsed specimens from larger cohorts revealed a lower frequency of MET 
amplification in resistant tumors compared with that reported by Engelman and Bean, 
ranging from 5 to 11% (32, 33).  Given the results of these two studies, combination 
therapy with MET kinase inhibitors and anti-EGFR drugs should be considered for 
patients whose tumors have become resistant to gefitinib or erlotinib and harbor MET 
amplification.  
One of the questions stemming from these studies is the origin of the cells displaying 
MET amplification: did the cell lines and the tumors harbor pre-existing MET-
amplified clones and did the drug simply create a favorable environment capable of 
selecting them? Or, alternatively, did the drug induce a stress able to promote DNA 
breaks in fragile sites, such as the one in which the MET gene is located (34)? To 
answer these questions, Turke and colleagues (35) analyzed the HCC827 NSCLC cell 
line that, upon gefitinib treatment, became resistant via MET amplification. When 
they studied the parental HCC827 cells using high-throughput FISH, they identified 6 
out of 4237 cells harboring a significant increase in MET copy number.  On the 
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contrary, they did not find any MET-amplified subpopulation in two other NSCLC 
cell lines, namely H3255 and PC-9, which, upon acquisition of resistance to gefitinib, 
displayed the EGFR secondary resistance mutation T790M but not MET 
amplification. To further validate these observations in the clinical setting, the authors 
evaluated specimens obtained from 27 patients who developed acquired resistance to 
either gefitinib or erlotinib and found MET amplification in 4 of these samples. In all 
of these patients, the pretreatment specimens revealed rare (<1%) tumor cells with 
MET amplification. In contrast, only 1 out of 8 cases of resistance to anti-EGFR drugs 
resulting from EGFR secondary resistance mutations displayed rare MET-amplified 
tumor cells. Altogether, these data suggest that MET-amplified tumor cells pre-exist 
and that these cells are selected during the course of therapy in patients and NSCLC 
cell lines that are characterized by MET amplification as a mechanism of secondary 
resistance to EGFR inhibitors. However, it remains to be clarified if this is true only in 
NSCLC or if it is a common feature of other cancers. 
Another interesting observation stemming from this work is that the presence of HGF 
in the environment, concomitant with EGFR inhibition, strongly favors the emergence 
of MET-amplified cells. In vitro experiments showed that the exposure of cells to 
HGF reduced the time required for the onset of resistance to EGFR inhibitors from 
several months to 14 days. Therefore, it is conceivable that, in the presence of EGFR 
inhibitors, HGF provides a proliferative advantage to cells with MET amplification 
and favors their clonal expansion. Thus, the combination of gene amplification and 
ligand-mediated activation represents a very powerful mechanism that renders lung 
cancer cells resistant to targeted therapies. 
  
HER2-positive metastatic breast cancer 
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Several studies have shown that in HER2-overexpressing or amplified breast cancers 
the anti-HER2 humanized recombinant monoclonal antibody trastuzumab, in 
combination with chemotherapy, was significantly more effective than chemotherapy 
alone, both in the metastatic and the adjuvant settings (36, 37). In spite of the 
effectiveness of this treatment, only one third of patients who are eligible for the 
treatment respond; moreover, most of the patients who initially respond show disease 
progression within 1 year of treatment. Among the mechanisms of resistance to 
trastuzumab treatment (38-40), a role for MET has been reported by Shattuck and 
colleagues (41), who found that inhibition of MET sensitizes cells to trastuzumab-
mediated growth inhibition, whereas MET activation protects cells against 
trastuzumab. Based on these results, Minuti et al. (42) recently evaluated the 
relationship between MET and HGF copy number and responsiveness to trastuzumab 
in 130 HER2-positive metastatic breast cancer patients using FISH. MET-positive 
cases (defined as ratio mean MET/mean CEP 7 > 2) had a significantly higher 
trastuzumab failure rate (44.4% vs 16%; P=0.001) and a significantly shorter time to 
progression (TTP; 5.7 vs 9.9 months; HR 1.74; P=0.006) compared with MET-
negative cases. Similar results were obtained when HGF FISH status was evaluated. 
Interestingly, MET and HGFpositivity were highly correlated (P<0.001), suggesting 
the presence of chromosome aneuploidy, rather than single amplification of either of 
the two genes. These results, together with the preclinical studies, suggest the possible 
effectiveness of combined anti-HER2 and anti-MET therapies in a subgroup of 
HER2-positive metastatic breast cancer patients.  
 
Colon cancer 
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The EGFR-targeted monoclonal antibodies cetuximab and panitumumab are effective 
in a subset of metastatic colorectal tumors. The presence of KRAS mutations and 
deregulation of effectors of the EGFR signaling cascade (PIK3CA, PTEN, NRAS) or 
of EGFR modulators (HER2, EGFR ligands) are thought to impair primary response 
to EGFR blockade (43-45). Moreover, all responding patients develop resistance, 
which occurs through emergence of KRAS mutations in approximately 50% of the 
cases (46, 47) . A recent report has shown that amplification of the MET proto-
oncogene can be responsible for de novo and acquired resistance to anti-EGFR 
therapy in colorectal cancer patients (48). Notably, in xenografts derived from MET-
amplified tumors, treatment with MET kinase inhibitors overcame resistance to EGFR 
blockade. These results highlight the role of MET in mediating primary and secondary 
resistance to anti-EGFR therapies in colorectal cancer and offer novel opportunities to 
design clinical studies with combined EGFR/MET inhibitors.  
 
Glioblastoma 
Recent work performed by Jun and colleagues (49) revealed a role of MET in 
mediating resistance to gefitinib in a pre-clinical model of glioblastoma multiforme. 
Inhibition of EGFR resulted in a substantial change in global gene expression levels 
and, in particular, increased MET expression, which resulted in sustained prosurvival 
Akt signaling. Pharmacological inhibition of MET overcame the resistance to EGFR 
inhibition, further supporting the wide importance of MET/EGFR interaction in 
multiple tumor types.      
        
A general problem: definition of MET amplification 
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Since these works imply a clinically relevant role for MET gene amplification in 
sustaining resistance to anti-EGFR therapies, a critical point is how to define MET 
amplification. Even though FISH seems to be the best way to identify MET gene copy 
number, standardized criteria to define MET FISH positive tumors have not yet been 
determined. The two most commonly used criteria are the University of Colorado 
Cancer Center Criteria (UICC) (50) and the Cappuzzo scoring system (51). Both of 
these scoring systems, however, evaluate aneuploidy and real MET amplification at 
the same time. From a biological point of view this can potentially confound the 
results, since chromosome 7, on which MET is located, also contains the genes for 
HGF and EGFR. Thus, chromosomal duplication increases not only the number of 
MET copies but also the copy number of its ligand and of EGFR, the therapeutic 
target. A recent work (52) has compared the Cappuzzo scoring system with the 
PathVysion system, which takes into account only real amplifications. The latter, in 
fact, considers a ratio between total MET copy number/Chr 7 copy number ≥ 2.0 as 
positive. The analysis performed on 138 lung adenocarcinoma patients revealed MET 
FISH positivity in 15% and 4% of cases according to the Cappuzzo scoring system 
and to PathVision, respectively. This means that in the great majority of cases, the 
increased MET copy number is not due to a real gene amplification but rather to 
chromosomal aneuploidy. Whether these two biological conditions are associated 
with a different clinical behavior should be assessed in future studies.  
What is the clinically relevant number of MET copies in order to confer resistance to 
targeted therapies? This question has been addressed by Suda et al. (53), who found 
that the MET gene copy number was augmented in proportion to erlotinib resistance 
in cells treated with increasing concentration of the drug. By using FISH analysis they 
observed that when MET gene copy number had increased by more than four-fold 
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(that is at least 8 gene copies), the cells were able to proliferate in the presence of 
micromolar concentrations of the drug, a clinically achievable dose. If these data hold 
true, the threshold suggested by the UICC and the Cappuzzo scoring systems might be 
too low to identify situations in which the level of MET amplification is high enough 
to have a strong clinical impact. However, it is essential to consider that since HGF is 
available in vivo, lower amplification levels can lead to ligand-dependent activation of 
the MET signaling pathway that is sufficient to drive resistance. At the moment, this 
question is still open and preclinical and clinical studies are needed to clarify this 
critical point.             
  
Non-cell autonomous role of MET in sustaining resistance to RTK inhibitors 
Cell autonomous or “intrinsic” mechanisms of resistance (such as activation of 
alternative signaling pathways, onset of secondary mutations in drug targets, 
amplification of the target gene, activation of efflux pumps) have been deeply 
investigated and therapeutic strategies and new drugs have been generated to 
overcome these molecular alterations. On the contrary, non-cell autonomous 
mechanisms of resistance to therapy have only recently been investigated. In fact, the 
concept that the tumor behaves as an organ, in which the interaction between cancer 
cells and the peritumoral environment is critical to sustain its survival, is relatively 
new. The first focus was on the role of angiogenesis and resulted in many studies 
aimed at blocking tumor growth by interfering with its vascularization (reviewed in 
(54). However, it soon became clear that other cells of the microenvironment, such as 
cancer-associated fibroblasts and inflammatory cells, can also modulate the biological 
properties of tumor cells, impacting on their growth and invasion potential (55). More 
recently it has been shown that the microenvironment can also contribute to both 
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primary and secondary resistance to anticancer therapies. Stromal cells, in fact, 
secrete factors able to activateredundant signaling programs in cancer cells that render 
them resistant to targeted treatments. One of the first reports to show this, from 
Williams et al. (56), found that in an animal model of BCR-ABL+ chronic 
myelogenous leukemia, neoplastic cells were sensitive to the ABL specific inhibitor 
imatinib only in vitro but not in vivo, due to the secretion of host cytokines.   
Several recent papers have highlighted the notion that HGF secreted by cells of the 
microenvironment can play a critical role in primary and secondary resistance to 
several target therapies in the context of different tumors.  
Using a panel of kinase-addicted human cancer cell lines, Wilson and colleagues (57), 
showed that most of these cells could be rescued from drug sensitivity by exposure to 
growth factors usually secreted by microenvironmental cells. HGF, FGF (fibroblast 
growth factor) and NRG1 (neuregulin 1) were the most broadly active ligands and 
could induce either a “partial rescue” or a “complete rescue” (that is a shift of the 
IC50 curve of more than ten-fold or a complete suppression of drug response) in the 
tested cell lines. The two downstream pathways commonly engaged by these ligand 
were the PI3K-AKT and MAPK pathways, but only HGF was able to simultaneously 
rescue both of these pathways. In the cell lines examined, HGF promoted resistance to 
several targeted therapies, including not only those against tyrosine kinases (such as 
ALK and members of the EGFR family), but also therapies against serine/threonine 
kinases (for example RAF).   
An important question is the following: how does the stimulation with HGF 
exert its role in promoting resistance? Does it simply activate downstream signals or, 
while doing so, does it also select cells able to better respond to HGF? A strong 
evidence in favor of the latter hypothesis was provided in the work of Turke et al. 
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(35), who showed that in EGFR-mutant NSCLCs, HGF treatment  promoted the 
emergence of cell subpopulations displaying MET amplification prior to exposure to 
the anti-EGFR drug gefitinib. Indeed, MET-amplified cells do not have any growth 
advantage in the absence of gefitinib, which targets EGFR-addicted cells, but they are 
enriched by the selective pressure of the drug during ligand exposure. Similar results 
were also obtained by Straussman et al. (58), who showed that HGF treatment could 
rapidly promote resistance to lapatinib (a HER2 inhibitor) in HER2-amplified breast 
cancer cells, likely by driving selection of a subpopulation of MET-amplified cells. 
HGF is an angiogenic factor (59) that is able to activate MET in endothelial 
cells, in part by inducing VEGF production and decreasing thrombospondin-1 
expression (60). Although anti-angiogenic therapies have shown efficacy and survival 
benefits in clinical trials, the majority of patients develop resistance during treatment 
and undergo progression. Several studies have suggested that factors such as FGF2 or 
platelet derived growth factor, produced by either cancer or stromal cells, can 
contribute to the onset of resistance (57, 61). Shojaei and colleagues (62) have shown 
that HGF production by the tumor stroma can also contribute to resistance to 
treatment with sunitinib, a multikinase inhibitor targeting the VEGF pathway. Indeed, 
they found that resistant tumors displayed a greater concentration of HGF and a high 
MET expression level in endothelial cells. They also showed that combinatorial 
treatment with sunitinib and an anti-MET TKI was more effective than sunitinib 
alone. Moreover, systemic injection of HGF conferred resistance to sunitinib 
treatment by sustaining tumor angiogenesis. Altogether, these data suggest that 
cotargeting of VEGF/HGF mediated pathways could be a strategy to circumvent 
resistance to anti-angiogenic therapies.     
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Melanoma 
The role of HGF in mediating resistance to RAF inhibition in melanomas was 
studied by Straussman et al. (58), who showed that HGF secretion by stromal cells 
resulted in the activation of MET and reactivation of PI3K-AKT and MAPK 
pathways and in primary resistance to RAF inhibition. Moreover, they found a 
significant correlation between HGF expression by stromal cells and primary 
resistance to RAF inhibition. Importantly, dual inhibition of RAF and either HGF or 
MET reversed drug resistance. Interestingly, none of the other 22 RTK ligands tested 
were able to rescue BRAF-mutated melanoma cells from the BRAF inhibitor. In 
accordance with what was described by Wilson et al., (52) among all the evaluated 
ligands, only HGF was able to simultaneously and efficiently activate both the PI3K-
AKT and MAPK pathways. These data suggest that a combined anti RAF and anti-
MET/HGF therapy might represent a useful option in patients affected by RAF-
mutated tumors, such as melanomas, colon cancer and glioblastomas.  
 
Non-small cell lung cancer  
The first paper showing that HGF can induce gefitinib resistance in lung 
adenocarcinomas with EGFR activating mutations was that of Yano et al. (63), who 
found that HGF acts by restoring PI3K-AKT activation via phosphorylation of MET 
(but not of EGFR or HER3); moreover, they showed that strong immunoreactivity for 
HGF was detected in patients displaying primary or secondary resistance to gefitinib.  
The same authors subsequently found that high HGF immunohistochemical reactivity 
was present in 29% of non-responding patients and that HGF expression was 
significantly higher in tumors with acquired resistance than in sensitive ones (64). 
Plasma levels of HGF were evaluated by Tanaka et al. (65), who observed that 
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administration of EGFR kinase inhibitors significantly increased plasma HGF levels 
15 days after treatment. Moreover, high levels of plasma HGF before treatment were 
found in patients with primary resistance to anti-EGFR drugs. Finally, Yamada et al. 
(66) recently showed that, in lung cancer, HGF can induce resistance not only to small 
TKIs but also to Cetuximab, an anti-EGFR monoclonal antibody, and that in 
preclinical in vivo models this is due to the secretion of HGF by stromal fibroblasts.  
 Data published by the same authors indicate that a similar HGF-mediated mechanism 
can induce resistance to ALK inhibitors in lung cancer cells addicted to an activated 
form of the tyrosine kinase ALK (67). ALK fusion proteins are present in 3-7% of 
unselected NSCLCs; treatment of these patients with ALK inhibitors showed a 
response rate of 54%, with a 91% disease control rate (partial response + stable 
disease (68)). However, almost all the responding patients developed resistance to 
treatment and underwent relapse. Resistance was due to several mechanisms such as 
ALK gene amplification, secondary mutations, or coactivation of other RTKs like 
EGFR and HER2 (69).  Yamada et al. showed that paracrine activation by either 
EGFR or MET ligands from the microenvironment can trigger resistance to ALK 
inhibitors. Similar results were also reported in vitro by Harbinski et al. (61). These 
data suggest that the dual MET/ALK inhibitor crizotinib may be more effective than 
more specific ALK inhibitors in treating NSCLCs expressing ALK fusion proteins. 
 
Breast, gastric and colorectal cancer 
 Triple negative breast cancers (that is, breast cancers negative for the 
expression of estrogen receptor, progesterone receptor and HER2) display EGFR 
overexpression in 54% of cases, but they are not responsive to EGFR-targeting drugs. 
Mueller et al. (70) showed that HGF treatment of breast cancer cells that are sensitive 
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to EGFR TKIs conferred resistance to treatment. Interestingly, EGFR silencing 
abrogated HGF-induced cell survival, indicating a critical role for EGFR/MET cross-
talk. These data support the hypothesis that poor efficacy in the clinical treatment of 
triple negative breast cancers overexpressing EGFR may be due to crosstalk between 
EGFR and MET. Thus, simultaneous targeting of both the receptors could be an 
effective therapeutic strategy.   
 More than 15% of gastric cancers display amplification of HER2. In vitro 
studies showed that lapatinib, a dual TKI targeting HER2 and EGFR, strongly 
decreased the viability of gastric cancer cells with amplified HER2 (71). However, 
HGF-mediated MET activation rescued cells form lapatinib-induced inhibition and 
reactivated downstream pathways. Finally, Liska et al. (72) showed that in colorectal 
cancer cells, HGF-induced MET activation could release cells from cetuximab-
mediated EGFR inhibition, suggesting that inhibition of the MET/HGF pathway may 
also improve the response to EGFR inhibitors in colorectal cancer.  
   
Clinical translation 
 The idea of targeting the HGF/MET axis as a strategy to avoid or circumvent 
resistance to molecular therapies seems very attractive in light of the preclinical data 
collected in the last few years. Recent works have shown that only a small number of 
oncogenic tyrosine kinases display a compensatory ability when the “driver” kinase is 
inhibited. Among the tested kinases, MET seems to be one of the most effective, since 
it simultaneously activates the RAS/MAPK and the PI3K/AKT pathways with high 
efficiency.  As previously described, preclinical experiments have shown that 
combinatorial treatments with a drug blocking the driver kinase plus a MET/HGF 
inhibitor delay the onset of secondary resistance or even overcome resistance to the 
21 
 
targeting treatment. Notably, clinical data also support the value of combining a 
MET/HGF inhibitor with already approved targeted therapies in order to delay patient 
relapse. In particular, a recent phase II clinical trial with MetMAb (Onartuzumab, a 
one-armed antibody designed to compete with HGF by binding the extracellular 
portion of MET) (73), performed in patients with advanced NSCLC has shown the 
clinical efficacy of the combined therapy. This Phase II study showed that patients 
whose tumors had high MET levels experienced a 2-fold increase in progression-free 
survival in response to METMAb plus erlotinib compared to erlotinib alone. 
Moreover, the combination of  METMAb plus erlotinib tripled the overall survival 
compared with erlotinib alone in patients harboring tumors with high MET expression 
(74). Overall, although this trial was not designed to investigate the role of MET in 
acquired EGFR TKI resistance, these results suggest that the combined anti 
EGFR/MET treatment can delay the onset of resistance. This is likely the 
consequence of preventing the outgrowth of clones displaying MET activation, which 
are favored in the presence of anti-EGFR drugs.  
A clinically relevant point is how to select patients who could benefit from the 
combined treatment. There are currently no available validated biomarkers that can be 
used to predict the molecular mechanisms that will sustain resistance in different 
patients. Therefore, at the moment, preventing resistance is more a dream than a close 
reality, since the presence of cell autonomous and non-cell autonomous mechanisms 
leaves many possibilities open. In addition, the clinical perspective is different in the 
case of patients with primary (innate) or secondary (acquired) resistance.  
With regard to primary resistance, preclinical models identified local increases 
in HGF /MET activation as possible reasons for resistance to target therapies. Relying 
on these data, it would be important to stratify patients on the basis of HGF/MET 
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status in the tumor, in order to select patients who could benefit from the treatment 
with a single agent and patients who would need a combined therapy with MET 
inhibitors.  The main problem related to this stratification is that, at present, no 
technique to quantify HGF or MET activation in patient-derived samples has been 
standardized and routinely used. In particular: 1) there are no anti-HGF antibodies of 
sufficient quality for routine use in a pathological setting. This issue could be 
overcome by the use of recently developed in  situ hybridization techniques (75). 
However, because of the high costs and the technical difficulties, this approach will 
likely be applicable only on a large-scale in the future; 2) the phosphorylation of 
tyrosine receptors such as MET is rapidly lost in cells and tissues at room 
temperature. Since adequate preservation of the surgical resection/biopsy is not 
routinely done, immunohistochemical analysis with antiphospho-MET antibodies or 
phosphoproteomic approaches would rarely be informative. Moreover, the lack of 
standard in anti-MET antibodies for IHC and in the scoring system to evaluate MET 
activation by IHC is a key limitation. These technical problems in evaluating MET 
activation in patient samples may also suggest that the involvement of the HGF/MET 
axis in primary and secondary resistance has probably been underestimated; and 3) 
intratumoral heterogeneity and multiple layers of mechanisms of pathway activation 
represent additional problems. 
 
With regard to secondary resistance, molecular analysis of the relapsed tissues 
is becoming mandatory, since many clinical studies have shown that the expression 
profile as well as the genomic status of the resistant tumors/metastases can be very 
different from that of the primary neoplasm. The identification of MET gene 
amplification in resistant samples will demand the use of a combined anti-EGFR/anti-
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MET therapy. This kind of analysis (evaluation of MET gene amplification upon 
relapse, for example by FISH) is, at present, not routinely performed in all centers, but 
it will probably become mandatory in the near future. In addition, it would be of great 
clinical impact to monitor the possible onset of MET gene amplification in the tumor 
during the treatment targeting the “driver” kinase (e.g. anti-EGFR drugs in lung 
cancer). It would thus be possible to foresee the development of resistance before the 
radiological appearance of the relapsed tumor and to start a combined therapy with 
MET inhibitors in advance of relapse. At the moment, the only known possibility to 
repeatedly monitor -to some extent- a tumor or a metastasis in a patient is by 
analyzing tumor-free DNA in the circulating blood (the recent concept of “liquid 
biopsy”). This strategy has been successfully used to identify the onset of acquired 
resistance to anti-EGFR antibodies in colorectal cancer due to KRAS mutations (47). 
However, since MET alterations implicated in the acquisition of resistance are 
quantitative and not qualitative (i.e. increased gene copy number and not mutations), 
their identification in the blood appears more difficult. 
To evaluate the efficacy of combined treatments in counteracting both primary 
and secondary resistance, it is now possible to use mouse models that mimic the 
complexity of a specific patient’s cancer.  In practical terms, immunocompromised 
mice can be directly engrafted with tumor surgical specimens/biopsies to obtain 
“xenopatients” that, even upon serial passages, retain the histological and genomic 
features of their original tumors (76).  Once the “signature” of a tumor is identified, 
different drugs or combinations can be tested in these “avatars”, to select the most 
efficient combination for the patient. Other than being feasible in relatively few 
cancer centers, the main problem to evaluate HGF or MET as therapeutic targets 
through this approach is the observation -often reported in the literature- of the low 
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cross-reactivity between human MET and murine HGF (77). The decreased ability of 
the mouse ligand to activate human MET could lead to the underestimation of the role 
played by the stromal murine HGF on tumor cells expressing human MET.  
 
CONCLUSIONS 
Recently, we have gained a better understanding of the molecular mechanisms 
underlying primary and secondary resistance to targeted therapies. According to 
Vogelstein (46), “only a limited number of genes are likely to be able to exert a 
resistance phenotype”, and recent studies have shown that the HGF/MET axis is one 
such pathway. Drugs that target this tyrosine kinase are now available and offer the 
opportunity to treat patients to overcome resistance, but the problem of identifying 
patients who could benefit most from these treatments still remains. Personalized 
approaches based on genomic and functional profiles will be critical to select these 
patients and to evaluate the complex behavior of their tumors over time.  
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FIGURE LEGENDS 
 
Figure 1. MET-induced signaling pathways and biological activities.  
Upper panel: Hepatocyte growth factor (HGF) promotes dimerization and activation 
of MET at the plasma membrane. The phopsphorylation of cytoplasmic tyrosines 
creates binding sites for several SH2-containing intracellular tranducers such as 
Growth factor receptor-bound protein 2 (Grb2), Grb2-Associated Binding protein 1 
(GAB1), phospholipase C PLC), Phosphoinositide 3-Kinase (PI3K), and Signal 
Transducer and Activator of Transcription 3 (STAT3). Signals originated by the RAS-
MAPK, PI3K-AKT and STAT3 pathways reach the nucleus and modulate gene 
transcription and DNA replication. RAC1-dependent signals control cytoskeletal 
modifications. Lower panels:  Invasive growth is a complex biological program which 
results from the combination of different biological activities (shown in the cartoon) 
such as proliferation, protection from apoptosis, motility and differentiation.  BM = 
basement membrane. 
 
Figure 2. MET interaction with other membrane receptors.  
The strength and duration of MET-induced signals are regulated by a network of co-
receptors (such as adhesive receptors, death receptors, B plexins and other tyrosine 
kinase receptors) that physically associate with MET. The roles taken on by these 
interactions are reported below the corresponding receptors.    
 
Figure 3. MET alterations in human tumors.  
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Deregulated MET activation in several human tumors can be due to different 
molecular alterations. (A) The most common mechanism is  MET overexpression in 
the absence of gene amplification, due to hypoxia, activation of upstream oncogenes, 
inactivation of tumor suppressor genes or loss of microRNAs. (B) MET gene 
amplification drives receptor overexpression and constitutive activation. (C) 
Activating germline mutations have been identified in patients affected by hereditary 
papillary renal carcinomas; somatic mutations, located either in the intracellular or in 
the extracellular domain, have been found in the indicted cancer types (D) Autocrine 
MET activation is generally due to ectopic MET expression in cells producing HGF.  
 
Figure 4. HGF/MET inhibitors in active clinical trials. 
Anti-MET inhibitors fall in two main categories: monoclonal antibodies directed 
against MET or HGF (upper panels) and small kinase inhibitors (lower panel). The 
table shows a list of the active clinical trials targeting either HGF or MET.   
 
Figure 5. Cell autonomous mechanisms of resistance to target therapies involving 
the HGF/MET axis.  
(A) MET gene amplification results in overexpression of the receptor and HER3 
transphosphorylation in NSCLC cells in which EGFR is inhibited by specific TKIs. 
(B) Chromosome 7 duplication results in increased copy number of both HGF and 
MET and, thus, in increased MET-dependent signal transduction. This results in 
resistance to trastuzumab in breast cancer cells. (C) Upon EGFR inhibition, a 
substantial increase of MET expression is responsible for sustained pro-survival AKT 
signaling, leading to resistance to EGFR TKIs in glioblastoma.  (D) MET gene 
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amplification, causing receptor overexpression and activation of downstream 
pathways, induces resistance to cetuximab and panitumumab in colorectal cancer. 
 
Figure 6. Non cell-autonomous mechanisms of resistance to target therapies 
involving the HGF/MET axis.  
(A) HGF secretion by stromal cells results in MET activation and stimulation of 
PI3K-AKT and MAPK pathways in tumor cells presenting BRAF activating 
mutations or constitutive RTK activation. This leads to resistance to inhibitors 
targeting BRAF or growth factor receptors, respectively. (B) HGF production by 
stromal cells can contribute to induce resistance to treatment with sunitinib by 
activating MET-dependent pathways in endothelial cells that compensate for VEGFR 
inhibition. 
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COMPOUND COMPANY FEATURES CLINICAL DEVELOPMENT 
FiclatuzuMAb 
(AV-299) 
AVEO MAb Phase II: NSCLC 
Phase I: solid tumors, 
limphoma, multiple mieloma 
RilotumuMAb  
(AMG-102) 
Amgen MAb Phase II: colorectal, 
prostate, renal cell and 
gynaecological cancer, 
mesothelioma, glioma,SCLC 
and NSCLC 
Phase III: gastro-esophageal 
cancer 
TAK-701 Millenium MAb Phase I: solid tumors 
(completed) 
OnartuzuMAb Genentech 
Roche 
MAb Phase II: NSCLC, breast 
and colorectal cancer.  
Phase III: NSCLC 
LY-2875358 Eli Lilly MAb Phase I: solid tumors, 
lymphoma 
Tivantinib ArQule Specific anti-MET 
TKI  
(non-ATP 
competitor) 
Phase II: NSCLC, gastric, 
colorectal, renal cell, head 
and neck , prostate cancer 
Phase III: NSCLC, 
Hepatocelular cancer 
EMD 1214063 
EMD 1204831 
EMD 
Serono 
Specific anti-MET 
TKI  
(ATP competitor) 
Phase I: solid tumors 
INCB28060 Novartis/ 
Incyte 
Specific anti-MET 
TKI  
(ATP competitor) 
Phase I: solid tumors 
Foretinib Glaxo 
SmithKline 
Non-Specific anti-
MET TKI (ATP 
competitor): MET, 
VEGFR2, AXL, 
PDGFR, KIT, 
FLT3,TIE2 
Phase II: NSCLC, breast, 
gastric, papillary renal and 
head and neck cancer.  
Crizotinib Pfizer Non-Specific anti-
MET TKI (ATP 
competitor): 
MET,ROS1, ALK, 
AXL,RON,TIE2 
Phase III: ALK-altered 
NSCLC 
Phase I and II:lung cancer, 
anaplastic large cell 
lymphoma and others 
Cabozantinib Exelixis Non-Specific anti-
MET TKI (ATP 
competitor): MET, 
VEGFR2, RET, KIT, 
FLT3,TIE2 
Phase III: medullary thyroid 
cancer, prostate cancer 
Phase II: NSCLC, brain, 
prostate , breast cancer and 
other solid tumors 
AMG 208 Amgen Non-Specific anti-
MET TKI (ATP 
competitor): MET, 
RON 
Phase I: solid tumors, 
lymphoma 
MGCD-265 Methylgene Non-Specific anti-
MET TKI (ATP 
competitor): MET, 
RON, VEGFR1, 
TIE2 
VEGFR2, VEGFR3,  
Phase II: NSCLC 
E7050 Eisai Non-Specific anti-
MET TKI (ATP 
competitor): MET, 
VEGFR2 
Phase II: Hepatocellular 
cancer, glioblastoma, 
melanoma, gastric cancer, 
head and neck cancer 
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MET TKIs 
Anti-HGF 
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